130 related articles for article (PubMed ID: 26864592)
21. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
Orouji A; Goerdt S; Utikal J; Leverkus M
Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
[No Abstract] [Full Text] [Related]
22. Skin eruption and cholestatic hepatic injury due to vismodegib.
Drago F; Trave I; Wei Y; Parodi A
G Ital Dermatol Venereol; 2019 Aug; 154(4):496-497. PubMed ID: 29199802
[No Abstract] [Full Text] [Related]
23. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
24. [High risk cerebellar medulloblastoma: the use of high doses of chemotherapy].
Benito Bernal A; Villa Alcázar M; Díaz Pérez MA; Madero López L
An Esp Pediatr; 1997 Dec; 47(6):647-50. PubMed ID: 9575128
[No Abstract] [Full Text] [Related]
25. Levocarnitine for vismodegib-associated muscle spasms: a pilot randomized, double-blind, placebo-controlled, investigator-initiated trial.
Cannon JGD; Tran DC; Li S; Chang AS
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e298-e299. PubMed ID: 29405443
[No Abstract] [Full Text] [Related]
26. Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance.
Ventarola DJ; Silverstein DI
J Am Acad Dermatol; 2014 Aug; 71(2):397-8. PubMed ID: 25037792
[No Abstract] [Full Text] [Related]
27. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
[No Abstract] [Full Text] [Related]
28. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
[No Abstract] [Full Text] [Related]
29. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH
JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175
[No Abstract] [Full Text] [Related]
30. High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma.
Dunkel IJ; Finlay JL
J Neurooncol; 1996 Jul; 29(1):69-74. PubMed ID: 8817417
[TBL] [Abstract][Full Text] [Related]
31. Blockade of estrogen receptor signaling to improve outlook for medulloblastoma sufferers.
Belcher SM
Future Oncol; 2009 Aug; 5(6):751-4. PubMed ID: 19663723
[No Abstract] [Full Text] [Related]
32. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
33. Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases.
Giuffrida R; Kashofer K; Dika E; Patrizi A; Baraldi C; Di Meo N; Zalaudek I
Eur J Cancer; 2018 Mar; 91():177-179. PubMed ID: 29373258
[No Abstract] [Full Text] [Related]
34. Perspectives: Chemotherapy of medulloblastoma.
Mastrangelo S; Tornesello A; Mastrangelo R
Med Pediatr Oncol; 1999 Aug; 33(2):116-9. PubMed ID: 10398188
[No Abstract] [Full Text] [Related]
35. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Wolfe CM; Green WH; Cognetta AB; Hatfield HK
Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
[No Abstract] [Full Text] [Related]
36. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
Yang X; Dinehart SM
JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
[No Abstract] [Full Text] [Related]
37. Hepatotoxicity Associated With Vismodegib: Could Dose Reduction Be an Effective Management?
de Perosanz-Lobo D; Burgos-Blasco P; Moreno-Arrones OM; Bea-Ardebol S
Dermatol Surg; 2021 Jul; 47(7):1006-1007. PubMed ID: 34167133
[No Abstract] [Full Text] [Related]
38. Vismodegib (Erivedge) for basal cell carcinoma.
Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
[No Abstract] [Full Text] [Related]
39. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
[TBL] [Abstract][Full Text] [Related]
40. Medulloblastoma--caution regarding new treatment approaches.
Kun LE; Constine LS
Int J Radiat Oncol Biol Phys; 1991 Apr; 20(4):897-9. PubMed ID: 2004969
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
